Uppsala, Sweden, April 1, 2021 – Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, today announces the appointment of Dr. Reinhard Koenig as Chief Scientific Officer with immediate effect, reporting to Dr. Francois Martelet, Chief Executive Officer.
Dr. Koenig, M.D. is an experienced executive with over 25 years’ experience at life-science companies, many of them operating internationally. He has a deep understanding of successful product development and commercialization of medicines in the fields of cancer, immunology, neurology, cardiology, critical care, dermatology, and a track record of obtaining approvals worldwide. Prior to working at Oasmia, Dr. Koenig held various positions ranging from subject matter specialist to C-level executive and director. Previous companies include Boehringer Mannheim, Genentech, Questcor and Piramal Critical Care, amongst others.
François Martelet, M.D., CEO of Oasmia, commented: “It has been a pleasure working with Reinhard in the position of Acting CMO /CSO of Oasmia over the last few months, so I am very pleased he has now accepted the position as CSO. The experience and contacts that he brings, together with his knowledge of our business, will be invaluable as we continue to implement our strategy of accelerating growth and generating long term value.”
Dr. Koenig, newly appointed CSO of Oasmia, said: “Oasmia is at an exciting time in its ongoing transformation. As Oasmia’s new CSO I look forward to continuing my work with Francois and the new leadership team. In addition to guiding the progress of Oasmia’s current development candidates, I am also looking forward to evaluating in-licensing and M&A opportunities to help build the product portfolio.”
For more information:
Oasmia Pharmaceutical AB
Francois Martelet, Chief Executive Officer
Phone: +46 18-50 54 40
Consilium Strategic Communications
Jonathan Birt, Chris Welsh, Ashley Tapp
Phone: +44 (0)20 3709 5700
About Oasmia Pharmaceutical AB
Oasmia is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on Oasmia’s proprietary drug delivery platform ™ which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar). Apealea has received market authorization in the European Union and several other territories for the treatment of first relapse in platinum-sensitive ovarian cancer, in combination with carboplatin. The Company is making Apealea accessible to patients through its partnership with Elevar Therapeutics, together with its existing commercial operations in the Nordic region. Oasmia’s shares are traded on the Nasdaq Stockholm stock exchange (ticker: OASM). To find out more about Oasmia please visit www.oasmia.com.